Leukemia, Myelomonocytic, Chronic
"Leukemia, Myelomonocytic, Chronic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.
Descriptor ID |
D015477
|
MeSH Number(s) |
C04.557.337.539.522 C15.378.190.615.510
|
Concept/Terms |
Leukemia, Myelomonocytic, Chronic- Leukemia, Myelomonocytic, Chronic
- Myelomonocytic Leukemia, Chronic
- Chronic Myelomonocytic Leukemia
- Chronic Myelomonocytic Leukemias
- Leukemia, Chronic Myelomonocytic
- Leukemias, Chronic Myelomonocytic
- Myelomonocytic Leukemias, Chronic
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, Myelomonocytic, Chronic".
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myelomonocytic, Chronic".
This graph shows the total number of publications written about "Leukemia, Myelomonocytic, Chronic" by people in this website by year, and whether "Leukemia, Myelomonocytic, Chronic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 2 | 0 | 2 |
1998 | 4 | 0 | 4 |
1999 | 2 | 0 | 2 |
2000 | 1 | 0 | 1 |
2002 | 2 | 0 | 2 |
2003 | 1 | 2 | 3 |
2004 | 1 | 1 | 2 |
2005 | 1 | 0 | 1 |
2006 | 4 | 1 | 5 |
2007 | 3 | 1 | 4 |
2008 | 2 | 1 | 3 |
2009 | 2 | 0 | 2 |
2010 | 2 | 1 | 3 |
2011 | 1 | 0 | 1 |
2012 | 2 | 0 | 2 |
2013 | 3 | 0 | 3 |
2014 | 5 | 1 | 6 |
2015 | 5 | 0 | 5 |
2016 | 3 | 0 | 3 |
2017 | 10 | 3 | 13 |
2018 | 11 | 0 | 11 |
2019 | 0 | 1 | 1 |
2020 | 6 | 0 | 6 |
2021 | 4 | 0 | 4 |
2022 | 7 | 1 | 8 |
2023 | 7 | 0 | 7 |
2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leukemia, Myelomonocytic, Chronic" by people in Profiles.
-
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol. 2024 Mar; 11(3):e186-e195.
-
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024 Jan; 11(1):e15-e26.
-
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. Am J Hematol. 2024 Feb; 99(2):E32-E36.
-
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. Br J Haematol. 2024 Mar; 204(3):898-909.
-
A case of sudden hearing loss in a patient with chronic myelomonocytic leukemia. Ann Hematol. 2023 Dec; 102(12):3427-3430.
-
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2023 11; 203(4):581-592.
-
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol. 2023 07 08; 16(1):73.
-
PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. Leuk Res. 2023 04; 127:107044.
-
The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica. 2023 01 01; 108(1):150-160.
-
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer. 2023 02 15; 129(4):560-568.